Share this video  

Tandem Meetings 2023 | Phase I study of pevonedistat and ibrutinib in R/R B-NHL

Swetha Kambhampati, MD, City of Hope, Duarte, CA, shares the results of a Phase I study of pevonedistat in combination with ibrutinib in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT03479268). The study reported that the combination was overall well-tolerated, and noted a promising efficacy in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter